文献速递血栓与止血造血干细胞移植与细胞治疗

非基因毒性抗体药物偶联物预处理实现血友病A小鼠安全有效的血小板基因治疗

Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
PubMed 文献 · Blood Adv · 2019-01-01

研究在血友病A小鼠中,用靶向CD45.2和CD117的抗体药物偶联物(ADC)进行非基因毒性预处理,替代传统放化疗,以支持基于造血干细胞的血小板特异性凝血因子VIII基因治疗。联合CD8靶向ADC可显著提高嵌合率和血小板FVIII表达,所有原代及二次受体均维持长期表达,并诱导免疫耐受、恢复止血、预防关节出血。

要点

  • CD45.2+CD117靶向ADC预处理可有效植入2bF8转导的造血干细胞。
  • 补充CD8靶向ADC后嵌合率和血小板FVIII表达显著提高,长期维持。
  • 基因治疗后诱导免疫耐受,尾出血试验止血恢复,针诱导膝损伤模型关节出血有效预防。

核心结论

  • 联合ADC介导的造血细胞靶向非基因毒性预处理高效且有利于血友病A小鼠的血小板特异性基因治疗。

研究设计与样本

  • 研究使用血友病A小鼠模型,采用由皂草素偶联CD45.2和CD117靶向抗体组成的抗体药物偶联物(ADC)进行非基因毒性预处理。

主要发现

  • CD45.2+CD117靶向ADC预处理下,三分之二接受2bF8慢病毒转导造血干细胞的血友病A小鼠维持持续治疗水平的血小板FVIII表达。
  • 补充CD8靶向ADC后,嵌合率和血小板FVIII表达显著增加,所有原代和二次受体均长期持续表达血小板FVIII。
  • 基因治疗后诱导免疫耐受,尾出血试验止血恢复,针诱导膝损伤模型中关节出血有效预防。

临床怎么用

  • 该非基因毒性预处理策略可能避免传统放化疗毒性,提高血友病A患者对造血干细胞基因治疗的接受度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy offers the potential to cure hemophilia A (HA). We have shown that hematopoietic stem cell (HSC)-based platelet-specific factor VIII (FVIII) (2bF8) gene therapy can produce therapeutic protein and induce antigen-specific immune tolerance in HA mice, even in the presence of inhibitory antibodies. For HSC-based gene therapy, traditional preconditioning using cytotoxic chemotherapy or total body irradiation (TBI) has been required. The potential toxicity associated with TBI or chemotherapy is a deterrent that may prevent patients with HA, a nonmalignant disease, from agreeing to such a protocol. Here, we describe targeted nongenotoxic preconditioning for 2bF8 gene therapy utilizing a hematopoietic cell-specific antibody-drug conjugate (ADC), which consists of saporin conjugated to CD45.2- and CD117-targeting antibodies. We found that a combination of CD45.2- and CD117-targeting ADC preconditioning was effective for engrafting 2bF8-transduced HSCs and was favorable for platelet lineage reconstitution. Two thirds of HA mice that received 2bF8 lentivirus-transduced HSCs under (CD45.2+CD117)-targeting ADC conditioning maintained sustained therapeutic levels of platelet FVIII expression. When CD8-targeting ADC was supplemented, chimerism and platelet FVIII expression were significantly increased, with long-term sustained platelet FVIII expression in all primary and secondary recipients. Importantly, immune tolerance was induced and hemostasis was restored in a tail-bleeding test, and joint bleeding also was effectively prevented in a needle-induced knee joint injury model in HA mice after 2bF8 gene therapy. In summary, we show for the first time efficient engraftment of gene-modified HSCs without genotoxic conditioning. The combined cocktail ADC-mediated hematopoietic cell-targeted nongenotoxic preconditioning that we developed is highly effective and favorable for platelet-specific gene therapy in HA mice.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gao C, Schroeder JA, Xue F, et al. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. Blood Adv. 2019. PMID: 31515232. doi:10.1182/bloodadvances.2019000516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。